Max Planck Society Ends Elsevier Subscription

The move is a show of support for Project DEAL and the open-access movement.

Written byAshley P. Taylor
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: Max Planck Institute for Biophysics
© ISTOCK.COM, OLLO

The Max Planck Society, an enormous German research organization 14,000 scientists strong and comprising multiple research institutes, has ended its subscription to Elsevier journals, the organization announced in a statement this Tuesday (December 18). It did so in support of the German open-access initiative called Project DEAL, after unsuccessful attempts to negotiate an open-access agreement with the publisher. The organization’s digital library will no longer have access to Elsevier’s approximately 2,500 journals, including The Lancet and Cell, once the subscription expires on December 31.

“The system of scholarly publishing today is a relic of the print era, and we want to activate a real paradigm shift in order to finally utilise the opportunities of the digital age,” says Gerard Meijer, director of the Max Planck Society’s (MPS) Fritz Haber Institute and a member of the DEAL negotiating team, in the statement.

Project ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform